within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD04_GlimepirideAndRosiglitaz;

model GlimepirideAndRosiglitaz
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 6.666666666666667e-08,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>GlimepirideAndRosiglitazone</td></tr><tr><td>ATC code:</td><td>A10BD04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.24</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Glimepiride and rosiglitazone is a fixed-dose combination of an oral sulfonylurea (glimepiride), which stimulates insulin secretion from pancreatic beta cells, and a thiazolidinedione (rosiglitazone), which improves insulin sensitivity in peripheral tissues. The combination is used for the management of type 2 diabetes mellitus in adults. The combination is approved for use in several countries, although rosiglitazone's approval status may vary due to cardiovascular safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects; individual PK studies generally report on monotherapy, as no published population PK model for the fixed-dose combination was identified.</p><h4>References</h4><ol><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=\"https://doi.org/10.2165/00003088-200544120-00002\">10.2165/00003088-200544120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16372821/\">https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Vaidyanathan, J, et al., &amp; Sahajwalla, CG (2012). Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. <i>Journal of pharmaceutical sciences</i> 101(5) 1659–1671. DOI:<a href=\"https://doi.org/10.1002/jps.23085\">10.1002/jps.23085</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22383396/\">https://pubmed.ncbi.nlm.nih.gov/22383396</a></p></li><li><p>Plosker, GL, &amp; Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. <i>PharmacoEconomics</i> 22(6) 389–411. DOI:<a href=\"https://doi.org/10.2165/00019053-200422060-00005\">10.2165/00019053-200422060-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15099124/\">https://pubmed.ncbi.nlm.nih.gov/15099124</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BD04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end GlimepirideAndRosiglitaz;
